Cdc20: A potential novel therapeutic target for cancer treatment

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3210-3214

  Wang, Zhiwei ^a   Wan, Lixin ^a   Zhong, Jiateng ^a,b   Inuzuka, Hiroyuki ^a   Liu, Pengda ^a   Sarkar, Fazlul H ^c   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Basic Medical College   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cdc20; Cell growth; Oncogene; Therapy; Ubiquitination

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN 20; CELL CYCLE PROTEIN 20 INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; KNOCKOUT MOUSE; LUNG NON SMALL CELL CANCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS; SPECIES SPECIFICITY; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84878833718     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319180005     Document Type: Review

References (54)

1. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-likeproteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776-88.
2. Frescas D, Pagano M. Deregulated proteolysis by the F-boxproteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-49.
3. Nakayama K I, Nakayama K. Ubiquitin ligases: cell-cycle controland cancer. Nat Rev Cancer 2006; 6: 369-81.
4. McLean J R, Chaix D, Ohi MD, Gould KL. State of the APC/C:organization, function, and structure. Crit Rev Biochem Mol Biol 2011; 46: 118-36.
5. Qiao X, Zhang L, Gamper AM, Fujita T, Wan Y. APC/C-Cdh1:from cell cycle to cellular differentiation and genomic integrity. Cell Cycle 2010; 9: 3904-12.
6. Eguren M, Manchado E, Malumbres M. Non-mitotic functions ofthe Anaphase-Promoting Complex. Semin Cell Dev Biol 2011; 22: 572-8.
7. Smolders L, Teodoro JG. Targeting the anaphase promotingcomplex: common pathways for viral infection and cancer therapy. Expert Opin Ther Targets 2011; 15: 767-80.
8. Hartwell LH, Culotti J, Reid B. Genetic control of the cell-divisioncycle in yeast. I. Detection of mutants. Proc Natl Acad Sci USA 1970; 66: 352-9.
9. Hartwell LH, Mortimer RK, Culotti J, Culotti M. Genetic Controlof the Cell Division Cycle in Yeast: V. Genetic Analysis of cdc Mutants. Genetics 1973; 74: 267-86.
10. Zur A, Brandeis M. Securin degradation is mediated by fzy and fzr,and is required for complete chromatid separation but not for cytokinesis. EMBO J 2001; 20: 792-801.
11. Lim H H, Goh P Y, Surana U. Cdc20 is essential for thecyclosome-mediated proteolysis of both Pds1 and Clb2 during M phase in budding yeast. Curr Biol 1998; 8: 231-4.
12. Shirayama M, Toth A, Galova M, Nasmyth K. APC(Cdc20)promotes exit from mitosis by destroying the anaphase inhibitor Pds1 and cyclin Clb5. Nature 1999; 402: 203-7.
13. Geley S, Kramer E, Gieffers C, et al. Anaphase-promotingcomplex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol 2001; 153: 137-48.
14. Ohtoshi A, Maeda T, Higashi H, Ashizawa S, Hatakeyama M. Human p55(CDC)/Cdc20 associates with cyclin A and is phosphorylated by the cyclin A-Cdk2 complex. Biochem Biophys Res Commun 2000; 268: 530-4.
15. Hames RS, Wattam SL, Yamano H, Bacchieri R, Fry AM. APC/C-mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. EMBO J 2001; 20: 7117-27.
16. Amador V, Ge S, Santamaria PG, Guardavaccaro D, Pagano M.APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 2007; 27: 462-73.
17. Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylationof Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 2010; 29: 2407-20.
18. Abbas T, Dutta A. p21 in cancer: intricate networks and multipleactivities. Nat Rev Cancer 2009; 9: 400-14.
19. Clarke DJ, Segal M, Andrews CA, et al. S-phase checkpointcontrols mitosis via an APC-independent Cdc20p function. Nat Cell Biol 2003; 5: 928-35.
20. Kidokoro T, Tanikawa C, Furukawa Y, et al. CDC20, a potentialcancer therapeutic target, is negatively regulated by p53. Oncogene 2008; 27: 1562-71.
21. Fang G, Yu H, Kirschner M W. The checkpoint protein MAD2 andthe mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 1998; 12: 1871-83.
22. Luo X, Fang G, Coldiron M, et al. Structure of the Mad2 spindleassembly checkpoint protein and its interaction with Cdc20. Nat Struct Biol 2000; 7: 224-9.
23. Reimann JD, Freed E, Hsu JY, et al. Emi1 is a mitotic regulatorthat interacts with Cdc20 and inhibits the anaphase promoting complex. Cell 2001; 105: 645-55.
24. Reimann JD, Gardner BE, Margottin-Goguet F, Jackson PK. Emi1regulates the anaphase-promoting complex by a different mechanism than Mad2 proteins. Genes Dev 2001; 15: 3278-85.
25. Fraschini R, Formenti E, Lucchini G, Piatti S. Budding yeast Bub2is localized at spindle pole bodies and activates the mitotic checkpoint via a different pathway from Mad2. J Cell Biol 1999; 145: 979-91.
26. Stegmeier F, Rape M, Draviam VM, et al. Anaphase initiation isregulated by antagonistic ubiquitination and deubiquitination activities. Nature 2007; 446: 876-81.
27. Song MS, Song SJ, Ayad NG, et al. The tumour suppressorRASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004; 6: 129-37.
28. Amin KS, Banerjee PP. The cellular functions of RASSF1A and itsinactivation in prostate cancer. J Carcinog 2012; 11: 3.
29. Wang J, Wang B, Chen X, Bi J. The prognostic value of RASSF1Apromoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 2011; 32: 411-6.
30. Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF. Nore1 andRASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol 2006; 407: 290-310.
31. Song SJ, Song MS, Kim SJ, et al. Aurora A regulatesprometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity. Cancer Res 2009; 69: 2314-23.
32. Foster SA, Morgan DO. The APC/C Subunit Mnd2/Apc15Promotes Cdc20 Autoubiquitination and Spindle Assembly Checkpoint Inactivation. Mol Cell 2012.
33. Mansfeld J, Collin P, Collins MO, Choudhary JS, Pines J. APC15drives the turnover of MCC-CDC20 to make the spindle assembly checkpoint responsive to kinetochore attachment. Nat Cell Biol 2011; 13: 1234-43.
34. Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintainsgenome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011; 20: 487-99.
35. Labit H, Fujimitsu K, Bayin NS, et al. Dephosphorylation of Cdc20is required for its C-box-dependent activation of the APC/C. EMBO J 2012; 31: 3351-62.
36. Lize M, Herr C, Klimke A, Bals R, Dobbelstein M. MicroRNA-449a levels increase by several orders of magnitude duringmucociliary differentiation of airway epithelia. Cell Cycle 2010; 9: 4579-83.
37. Yamanaka S, Campbell NR, An F, et al. Coordinated effects ofmicroRNA-494 induce G 2/M arrest in human cholangiocarcinoma. Cell Cycle 2012; 11.
38. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation byRNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011; 11: 644-56.
39. Esquela-Kerscher A, Slack F J. Oncomirs microRNAs with a rolein cancer. Nat Rev Cancer 2006; 6: 259-69.
40. Baumgarten AJ, Felthaus J, Wasch R. Strong inducible knockdownof APC/CCdc20 does not cause mitotic arrest in human somatic cells. Cell Cycle 2009; 8: 643-6.
41. Li M, York JP, Zhang P. Loss of Cdc20 causes a securin-dependentmetaphase arrest in two-cell mouse embryos. Mol Cell Biol 2007; 27: 3481-8.
42. Manchado E, Guillamot M, de Carcer G, et al. Targeting mitoticexit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell 2010; 18: 641-54.
43. Jiang J, Jedinak A, Sliva D. Ganodermanontriol (GDNT) exerts itseffect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA. Biochem Biophys Res Commun 2011; 415: 325-9.
44. Rajkumar T, Sabitha K, Vijayalakshmi N, et al. Identification andvalidation of genes involved in cervical tumourigenesis. BMC Cancer 2011; 11: 80.
45. Marucci G, Morandi L, Magrini E, et al. Gene expression profilingin glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 2008; 453: 599-609.
46. Ouellet V, Guyot MC, Le Page C, et al. Tissue array analysis ofexpression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006; 119: 599-607.
47. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA.Identification of common differentially expressed genes in urinary bladder cancer. PLoS One 2011; 6: e18135.
48. Kim JM, Sohn HY, Yoon SY, et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 2005; 11: 473-82.
49. Kato T, Daigo Y, Aragaki M, et al. Overexpression of CDC20predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 2012.
50. Chang DZ, Ma Y, Ji B, et al. Increased CDC20 expression isassociated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 2012; 5: 15.
51. Zeng X, Sigoillot F, Gaur S, et al. Pharmacologic inhibition of theanaphase-promoting complex induces a spindle checkpointdependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010; 18: 382-95.
52. Jiang J, Thyagarajan-Sahu A, Krchnak V, et al. NAHA, a novelhydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS One 2012; 7: e34283.
53. Jiang J, Sliva D. Novel medicinal mushroom blend suppressesgrowth and invasiveness of human breast cancer cells. Int J Oncol 2010; 37: 1529-36.
54. Huang H C, Shi J, Orth JD, Mitchison TJ. Evidence that mitoticexit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009; 16: 347-58.